Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs230D1-CRM197 + R21 + Matrix-M1
- Development stage
- Phase 2
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Pfs230D1-CRM197 + R21 + Matrix-M1 is a **multi-component malaria vaccine candidate** composed of three constituents: **Pfs230D1-CRM197**, a conjugate of the Pfs230 domain 1 (a sexual-stage malaria surface antigen from Plasmodium falciparum) chemically linked to CRM197 (a non-toxic mutant of diphtheria toxin serving as a carrier protein); **R21**, a next-generation subunit vaccine based on the fusion of Plasmodium falciparum circumsporozoite protein (CSP) with hepatitis B surface antigen (HBsAg), designed to elicit immune responses against the parasite's sporozoite stage; and **Matrix-M1**, a saponin-based adjuvant developed to boost immune responses. The combination simultaneously targets both the transmission (sexually developed) and pre-erythrocytic (sporozoite) stages of malaria, aiming to provide robust immunity that blocks infection and transmission. The main indication is the prevention of malaria, with current trials focusing on pediatric and adult populations in endemic regions[1][4][5][8].
- Other names
- Pfs230D1-CRM197 + R21 in Matrix-M1R21/Matrix-M1 + Pfs230D1-CRM197Pfs230D1-CRM197/R21/Matrix-M1
02
Targets
Pfs230HBsAg (Hepatitis B surface antigen)CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on Pfs230D1-CRM197 + R21 + Matrix-M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs230D1-CRM197 + R21 + Matrix-M1.